Lawson Health Research Institute will receive more than $1 million of the $5.4 million from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada to support research into medical isotope alternatives.
The funding will assist in the validation and clinical testing of a modified technetium-99m formulation. The new patented product is optimized for use in the diagnosis and monitoring of the spread of breast cancer through sentinel node imaging, according to Lawson.
The London, Ontario-based research center said the new technetium-99m formulation exhibits optimal size for lymph node detection and does not require a filtration step that wastes 70 to 90 percent of the radioactivity.
The product may also eventually prove useful as an alternative to other technetium-99m formulations in liver, spleen and bone marrow imaging, according to Lawson.